Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Quoin Pharmaceuticals director Natalie Ee Mun Leong reported an award of a share option on 08/21/2025 exercisable for 4,105 American Depositary Shares (ADSs) representing underlying ordinary shares. The option’s stated exercise price is $9.07 per ADS. The grant was approved by the Compensation Committee and Board on May 29, 2025 and was subsequently approved by shareholders on August 21, 2025. The option vests over four annual installments: 20% on each of May 29, 2026, 2027 and 2028, and 40% on May 29, 2029.
Anthony James Culverwell, a director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted a stock option on 08/21/2025 covering 13,682 American Depositary Shares (ADSs) with an exercise price of $9.07 per ADS. Each ADS represents 35 ordinary shares, so the option covers the ADS-denominated equivalent of the underlying ordinary shares.
The option was approved by the Compensation Committee and Board on 05/29/2025 and became effective upon shareholder approval on 08/21/2025. The award vests over four annual installments: 20% vesting on each of 05/29/2026, 05/29/2027 and 05/29/2028, and 40% vesting on 05/29/2029. The reported ownership following the grant is 13,682 ADSs, held directly.
Quoin Pharmaceuticals, Ltd. (QNRX) director Dennis Langer was granted a share option to purchase 13,682 ADSs on August 21, 2025, as reported on Form 4 filed August 25, 2025. The option is stated in ADS terms with an exercise price of $9.07 per ADS; each ADS represents 35 ordinary shares. The grant was approved by the Compensation Committee and Board on May 29, 2025, subject to shareholder approval, and shareholders approved it on August 21, 2025. The option vests in four annual installments: 20% on each May 29 of 2026, 2027 and 2028, and 40% on May 29, 2029.
Quoin Pharmaceuticals Ltd. furnished a Form 8-K reporting corporate governance and personnel items. The filing lists several governance topics including the submission of matters to a vote of security holders, a material modification to rights of security holders, departures and elections of directors or certain officers, and compensatory arrangements for officers. The document discloses one specific executive term: Ms. Lawlor will be entitled to 28 days' annual leave in each calendar year (in addition to statutory public holidays). The Form 8-K was executed by the company's Chief Executive Officer.
Quoin Pharmaceuticals (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical company, announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for their lead asset QRX003, targeting Netherton Syndrome. This significant regulatory milestone was disclosed in an 8-K filing dated June 24, 2025.
The RPD designation for QRX003 represents an important development in the company's rare and orphan disease pipeline, potentially accelerating the path to market for their Netherton Syndrome treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) filed a Form 8-K to announce that its Board has scheduled the 2025 Annual General Meeting of Shareholders ("2025 AGM") for August 21, 2025. Because this date is more than 30 days earlier than the anniversary of the 2024 AGM, previously disclosed shareholder-proposal deadlines are no longer valid.
Revised submission windows:
- Rule 14a-8 proposals: must be received by June 30, 2025 for inclusion in the Company’s proxy materials.
- Universal proxy (Rule 14a-19) director nominations: notice must also be delivered by June 30, 2025, the 10th calendar day after this report’s public announcement.
No financial results, transactions, or strategic changes were disclosed. The filing is primarily a procedural notice affecting shareholders who intend to submit proposals or nominate directors.